Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$7.92
+0.04 (+0.51%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $266.1M · quality 59.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.3B
P/E
99.0x
↑EV/EBITDA
12.0x
↓ROE
2.2%
↑Gross Margin
22.1%
↓Debt/Equity
0.60
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+0.9%
FCF CAGR
+182.0%
FCF margin
6.2%
FCF / Net income
3.20x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.77B · net income $112.3M · FCF $359.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.77B | $5.77B | $6.23B | $6.15B | $5.62B |
| Net Income | $112.3M | $112.3M | $394.6M | $246.2M | $138.0M |
| EBITDA | $676.1M | $676.1M | $910.9M | $733.3M | $596.3M |
| EPS | 0.12 | 0.12 | 0.44 | 0.28 | 0.15 |
| Gross Margin | 22.1% | 22.1% | 24.0% | 24.7% | 22.2% |
| Operating Margin | 4.8% | 4.8% | 6.8% | 6.4% | 5.2% |
| Net Margin | 1.9% | 1.9% | 6.3% | 4.0% | 2.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.60 | 0.60 | 0.72 | 0.80 | 0.85 |
| Current Ratio | 1.53 | 1.53 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $359.3M | $359.3M | $123.6M | $266.1M | $16.0M |
| Returns | |||||
| ROE | 2.2% | 2.2% | 10.1% | 6.8% | 4.1% |
| Valuation | |||||
| P/E | 99.00 | 99.00 | 21.55 | 25.11 | 45.53 |
| EV/EBITDA | 12.04 | 12.04 | 11.60 | 11.26 | 14.17 |
| P/B | 1.45 | 1.45 | 2.17 | 1.71 | 1.87 |
| Growth & Yield | |||||
| Revenue Growth | -7.5% | -7.5% | 1.4% | 9.3% | — |
| EPS Growth | -72.7% | -72.7% | 57.1% | 86.7% | — |
| Dividend Yield | 1.7% | 1.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
80.3%
EPS terminal req.
$0.70
Spread vs growth
-153.0%
5Y implied EPS CAGR
47.9%
EPS terminal req.
$0.85
Spread vs growth
-120.7%
10Y implied EPS CAGR
27.6%
EPS terminal req.
$1.37
Spread vs growth
-100.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-24.0%
Start / end P/E
24.2x → 66.0x
EPS bridge
0.44 → 0.12
Residual
-125.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.